InterVenn Demonstrates Power of Its GlycoVision™ Platform In Advanced Adenoma and Colorectal Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Biomarker--InterVenn Biosciences, the life science company pioneering glycoproteomics, presented new data at the 2023 Digestive Disease Week (DDW) annual conference, which was honored as a “Poster of Distinction”. This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™, analyzed 575 retrospective samples and was...
